Omeros Corp., a Seattle-based drug company focused on receptor and enzyme therapeutics, has filed for a $115 million IPO. It plans to trade on the Nasdaq under ticker symbol OMER, with Deutsche Bank Securities serving as lead underwriter.
The company has raised approximately $110 million in total VC funding, from firms like ARCH Venture Partners, Aravis Ventures, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, Trevi Health Ventures and WRF Capital. www.omeros.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.